Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 mass balance and pharmacokinetics study of [14C]-nanatinostat in advanced solid tumors
NL-OMON51840Phase 1Withdrawn
- Sponsor
- Viracta Therapeutics, Inc.
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nanatinostat in Nonhematologic neoplasms, sponsored by Viracta Therapeutics, Inc. Primary endpoint: Radioactivity excreted in urine and feces. Planned start Jun 2022; status: withdrawn.
02
Drugs
nanatinostat
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON51840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51840.